LABCORP HOLDINGS INC. — fact timeline

LABCORP HOLDINGS INC. reported first quarter ended March 31, 2026 results: revenue $3.54 billion, net income Net Earnings Attributable to Labcorp Holdings Inc. $ 277.8 $ 212.8, EPS $3.35. Guidance raised.

“Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance • Results from Operations for first quarter 2026 versus first quarter 2025: ◦ Revenue: $3.54 billion vs. $3.35 billion, up 5.8% ◦ Diluted EPS: $3.35 vs. $2.52, up 32.8% ◦ Adjusted EPS: $4.25 vs. $3.84, up 10.6% • Raised Full-Year Enterprise Revenue and Adjusted EPS guidance: ◦ Revenue guidance of 5.0% to 6.1%; up 20 basis points at the midpoint ◦ Adjusted EPS range of $17.70 to $18.35; up 13 cents at the midpoint”

LABCORP HOLDINGS INC. entered into Credit Agreement with Wells Fargo Bank, National Association valued at $750,000,000 (effective 2026-03-20).

“Labcorp Holdings Inc. (the “Company”), as parent guarantor, and Laboratory Corporation of America Holdings (“LCAH”), as borrower, entered into a Term Loan Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, National Association (“Wells Fargo”), as administrative agent, Wells Fargo Securities, LLC, as joint lead arranger and sole bookrunner, PNC Capital Markets LLC, as joint lead arranger, PNC Bank, National Association, as syndication agent, and the lenders from time to time party thereto, which provides for a $750,000,000 senior unsecured term loan (the “Term Loan”) scheduled to mature on March 20, 2028.”

LABCORP HOLDINGS INC. incurred term loan of $750,000,000 with Wells Fargo Bank, National Association (as administrative agent), Wells Fargo Securities, LLC (as joint lead arranger and sole bookrunner), PNC Capital Markets LLC (as joint lead arranger), PNC Bank, National Association (as syndication agent), and the lenders from time to time party thereto at floating rate equal to either (i) a SOFR-based rate plus a margin of 0.700% or ( maturing March 20, 2028.

“On March 20, 2026 (the “Closing Date”), Labcorp Holdings Inc. (the “Company”), as parent guarantor, and Laboratory Corporation of America Holdings (“LCAH”), as borrower, entered into a Term Loan Credit Agreement (the “Credit Agreement”) with Wells Fargo Bank, National Association (“Wells Fargo”), as administrative agent, Wells Fargo Securities, LLC, as joint lead arranger and sole bookrunner, PNC Capital Markets LLC, as joint lead arranger, PNC Bank, National Association, as syndication agent, and the lenders from time to time party thereto, which provides for a $750,000,000 senior unsecured term loan (the “Term Loan”) scheduled to mature on March 20, 2028.”

LABCORP HOLDINGS INC. amended Receivables Purchase Agreement with PNC Bank, National Association valued at $125 million accordion facility (effective 2026-01-28).

“On January 28, 2026, Labcorp Holdings Inc. (the “Company”) amended its receivables purchase agreement (as amended, the “Receivables Purchase Agreement”) by entering into the Second Amendment to the Receivables Purchase Agreement (the “RPA Amendment”), among Labcorp Receivables LLC (“Labcorp Receivables”), Laboratory Corporation of America Holdings, PNC Bank, National Association, as administrative agent and the other parties thereto and acknowledged and agreed by the Company.”

Glenn Eisenberg retired as Executive Vice President and Chief Financial Officer at LABCORP HOLDINGS INC..

“On November 19, 2024, Labcorp Holdings Inc. (“Labcorp”) announced that on November 15, 2024, Glenn Eisenberg notified Labcorp of his intention to retire from Labcorp effective April 30, 2025.”

Julia Wang was appointed as Executive Vice President and Chief Financial Officer at LABCORP HOLDINGS INC..

“Julia Wang, age 54, was appointed to the position of Executive Vice President and Chief Financial Officer ("CFO").”

LABCORP HOLDINGS INC. underwent a change of control involving Laboratory Corporation of America Holdings (closed 2024-05-17).

“On May 17, 2024, Labcorp implemented the Reorganization pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated as of May 17, 2024, among Labcorp, Labcorp Holdings Inc., a Delaware corporation (“Labcorp Holdings”) and Radiance Merger Sub Inc., a Delaware corporation and direct, wholly owned subsidiary of Labcorp Holdings (“Merger Sub”).”

LABCORP HOLDINGS INC. entered into Guarantor Joinder Agreement with Bank of America, N.A. (effective 2024-05-17).

“On May 17, 2024, Labcorp Holdings entered into the Guarantor Joinder Agreement (the “Guarantor Joinder Agreement"), pursuant to which, among other things, Labcorp Holdings provided a full and unconditional guarantee of Labcorp’s obligations under the Third Amended and Restated Credit Agreement”

LABCORP HOLDINGS INC. entered into Seventeenth Supplemental Indenture with U.S. Bank Trust Company, National Association (effective 2024-05-17).

“on May 17, 2024, Labcorp, Labcorp Holdings and U.S. Bank Trust Company, National Association (the “Trustee”) entered into a seventeenth supplemental indenture (the “Seventeenth Supplemental Indenture") to the indenture, dated as of November 19, 2010 between Labcorp and the Trustee”

LABCORP HOLDINGS INC. entered into Merger Agreement with Merger Sub (effective 2024-05-17).

“On May 17, 2024, Labcorp completed the Reorganization by implementing the Merger pursuant to the terms of the Merger Agreement.”

LABCORP HOLDINGS INC. shareholders rejected Shareholder proposal regarding report on transport of nonhuman primates at the 2024-05-14 meeting.

“Proposal 5. The Company's shareholders did not approve the shareholder proposal seeking an annual Board report on the transport of nonhuman primates within the United States. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 5,787,586 64,071,818 943,785 6,254,885”

LABCORP HOLDINGS INC. shareholders rejected Shareholder proposal regarding policy on golden parachutes at the 2024-05-14 meeting.

“Proposal 4. The Company's shareholders did not approve the shareholder proposal requesting adoption of a policy regarding shareholder opportunity to vote on excessive golden parachutes. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 5,219,140 65,530,226 53,823 6,254,885”

LABCORP HOLDINGS INC. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm at the 2024-05-14 meeting.

“Proposal 3. The Company's shareholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2024. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 76,120,507 832,250 105,317 0”

LABCORP HOLDINGS INC. shareholders approved Advisory vote on executive compensation at the 2024-05-14 meeting.

“Proposal 2. The Company's shareholders approved in an advisory (non-binding) vote, the compensation of the Company's named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 65,007,331 5,566,884 228,974 6,254,885”

LABCORP HOLDINGS INC. shareholders approved Election of Directors at the 2024-05-14 meeting.

“Proposal 1. The Company's shareholders elected the following persons, who were listed in the Proxy Statement, to the Board of Directors of the Company (the “Board”) to hold office for the term expiring at the 2025 Annual Meeting of Shareholders or until their successors are elected and qualified or until their earlier death, resignation, or removal: Votes For Votes Against Abstentions Broker Non-Votes Adam H. Schechter 66,696,331 3,866,647 240,211 6,254,885”

LABCORP HOLDINGS INC. reported first quarter ended March 31, 2024 results: revenue $3.18 billion, net income $228.3 million, EPS $2.69. Guidance raised.

“Labcorp Announces 2024 First Quarter Results Updates Full-Year Guidance • Results from Continuing Operations for first quarter 2024 versus last year: ◦ Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7% ◦ Diluted EPS: $2.69 versus $2.34 ◦ Adjusted EPS: $3.68 versus $3.46 • Full-Year 2024 Guidance: Raised midpoint and”